ENTA Stock Price, Enanta Pharmaceuticals Quote, Chart

Market Summary

USD12.93+0.28

Market Closed

2.21%

ENTA Alerts

Losses in recent quarter

ENTA Stock Price

View Fullscreen

ENTA RSI Chart

ENTA Valuation

Market Cap

273.8M

Price/Earnings (Trailing)

-2.08

Price/Sales (Trailing)

3.76

EV/EBITDA

-1.81

Price/Free Cashflow

-2.42

ENTA Price/Sales (Trailing)

ENTA Profitability

EBT Margin

-178.25%

Return on Equity

-79.3%

Return on Assets

-31.85%

Free Cashflow Yield

-41.37%

ENTA Fundamentals

ENTA Revenue

Revenue (TTM)

72.9M

Rev. Growth (Yr)

-4.16%

Rev. Growth (Qtr)

-5.27%

ENTA Earnings

Earnings (TTM)

-131.7M

Earnings Growth (Yr)

17.26%

Earnings Growth (Qtr)

6.74%

Breaking Down ENTA Revenue

Last 7 days

-11.4%

Last 30 days

-21.4%

Last 90 days

5.0%

Trailing 12 Months

-48.9%

How does ENTA drawdown profile look like?

ENTA Financial Health

Current Ratio

6.43

ENTA Investor Care

Shares Dilution (1Y)

0.59%

Diluted EPS (TTM)

-6.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	72.9M	0	0	0
2023	81.2M	80.6M	79.2M	73.6M
2022	91.6M	89.4M	86.2M	82.1M
2021	94.2M	97.1M	97.1M	93.0M
2020	175.9M	150.2M	122.5M	101.6M
2019	234.0M	221.1M	205.2M	187.9M
2018	165.6M	215.3M	206.6M	238.4M
2017	46.2M	39.7M	102.8M	130.5M
2016	87.5M	89.8M	88.3M	50.2M
2015	179.6M	149.1M	160.9M	131.8M
2014	6.1M	46.5M	47.7M	124.3M
2013	36.9M	34.5M	32.1M	5.1M
2012	0	0	41.7M	39.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Enanta Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 26, 2024	gardiner nathaniel s.	acquired	46,631	8.99	5,187	chief legal officer
Feb 12, 2024	luu brendan	sold (taxes)	-12,074	12.41	-973	chief business officer
Feb 12, 2024	kieffer tara lynn	acquired	-	-	3,320	chief product strategy officer
Feb 12, 2024	luly jay r.	sold (taxes)	-19,657	12.41	-1,584	president and ceo
Feb 12, 2024	mellett paul j	sold (taxes)	-12,074	12.41	-973	chief fin. & admin officer
Feb 12, 2024	gardiner nathaniel s.	sold (taxes)	-12,074	12.41	-973	chief legal officer
Feb 12, 2024	luly jay r.	acquired	-	-	5,400	president and ceo
Feb 12, 2024	luu brendan	acquired	-	-	3,320	chief business officer
Feb 12, 2024	or yat sun	acquired	-	-	3,680	chief scientific officer
Feb 12, 2024	gardiner nathaniel s.	acquired	-	-	3,320	chief legal officer

Which funds bought or sold ENTA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	Clearstead Trust, LLC	unchanged	-	40,765	88,418	0.02%
May 10, 2024	Covestor Ltd	reduced	-20.00	-	-	-%
May 10, 2024	PNC Financial Services Group, Inc.	added	905	35,560	37,574	-%
May 10, 2024	VANGUARD GROUP INC	added	7.49	16,784,700	33,664,200	-%
May 10, 2024	ACADIAN ASSET MANAGEMENT LLC	added	1.3	6,980,000	14,906,000	0.05%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	303	376,776	434,910	-%
May 10, 2024	OSAIC HOLDINGS, INC.	added	2,590	5,065	5,168	-%
May 10, 2024	BlackRock Inc.	reduced	-4.94	13,904,300	32,109,900	-%
May 10, 2024	JPMORGAN CHASE & CO	reduced	-8.47	991,076	2,410,300	-%
May 10, 2024	CORNERCAP INVESTMENT COUNSEL INC	added	1.84	113,312	240,686	0.04%

Are Funds Buying or Selling ENTA?

Are funds buying ENTA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ENTA

No. of Funds

ENTA Alerts

Losses in recent quarter

Unveiling Enanta Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.80%	2,064,000	SC 13G/A
Feb 13, 2024	vanguard group inc	8.52%	1,793,786	SC 13G/A
Jan 26, 2024	farallon capital partners, l.p.	1.8%	379,200	SC 13G/A
Jan 24, 2024	blackrock inc.	9.2%	1,934,711	SC 13G/A
Jan 22, 2024	state street corp	2.02%	425,640	SC 13G/A
Jan 11, 2024	millennium management llc	6.2%	1,314,949	SC 13G
Nov 16, 2023	millennium management llc	4.9%	1,024,676	SC 13G
Oct 06, 2023	blackrock inc.	9.4%	1,978,011	SC 13G/A
Feb 14, 2023	armistice capital, llc	9.99%	2,078,000	SC 13G
Feb 14, 2023	first manhattan co	1.17%	243,718	SC 13G/A

Recent SEC filings of Enanta Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	S-8	Employee Benefits Plan
May 06, 2024	8-K	Current Report
May 01, 2024	3	Insider Trading
May 01, 2024	4	Insider Trading
Mar 12, 2024	8-K	Current Report
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading

Peers (Alternatives to Enanta Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Enanta Pharmaceuticals Inc News

Latest updates

Enanta Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-5.3%	17,054,000	18,003,000	18,932,000	18,892,000	17,795,000	23,585,000	20,317,000	19,479,000	18,716,000	27,648,000	23,575,000	21,624,000	20,132,000	31,743,000	23,631,000	18,653,000	27,619,000	52,570,000	51,313,000	44,367,000	39,631,000
Costs and Expenses	-5.8%	49,820,000	52,889,000	49,962,000	55,605,000	57,246,000	53,598,000	47,365,000	52,019,000	52,563,000	58,057,000	57,302,000	55,471,000	49,832,000	44,042,000	43,414,000	41,505,000	39,494,000	39,699,000	44,882,000	40,612,000	40,935,000
S&GA Expenses	-100.0%	-	16,518,000	13,795,000	12,618,000	13,778,000	12,696,000	12,569,000	12,929,000	10,476,000	9,508,000	8,356,000	8,477,000	8,326,000	7,377,000	6,728,000	6,823,000	6,884,000	6,921,000	6,163,000	6,151,000	6,780,000
R&D Expenses	-2.2%	35,585,000	36,371,000	36,167,000	42,987,000	43,468,000	40,902,000	34,796,000	39,090,000	42,087,000	48,549,000	48,946,000	46,994,000	41,506,000	36,665,000	36,686,000	34,682,000	32,610,000	32,778,000	38,719,000	34,461,000	34,155,000
EBITDA Margin	6.0%	-1.59	-1.70	-1.56	-1.53	-1.51	-1.44	-1.38	-1.41	-1.39	-1.32	-1.07	-0.92	-	-	-	-	-	-	-	-	-
Interest Expenses	-25.5%	2,563,000	3,441,000	3,151,000	1,997,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	41.6%	-363,000	-622,000	-1,410,000	4,221,000	44,000	-34,000	32,000	-447,000	-	-36,000	-15,905,000	-9,384,000	7,110,000	-3,294,000	10,707,000	-7,142,000	-3,920,000	1,504,000	-486,000	-866,000	-3,204,000
Earnings Before Taxes	7.4%	-31,520,000	-34,029,000	-29,517,000	-34,844,000	-37,614,000	-29,020,000	-26,316,000	-32,147,000	-33,592,000	-30,151,000	-33,394,000	-33,408,000	-29,155,000	-11,622,000	-18,634,000	-21,407,000	-9,925,000	14,947,000	8,705,000	6,170,000	941,000
EBT Margin	3.5%	-1.78	-1.85	-1.65	-1.59	-1.54	-1.47	-1.42	-1.45	-1.43	-1.36	-1.11	-0.96	-	-	-	-	-	-	-	-	-
Net Income	6.7%	-31,157,000	-33,407,000	-28,107,000	-39,065,000	-37,658,000	-28,986,000	-26,348,000	-31,700,000	-33,592,000	-30,115,000	-24,599,000	-24,024,000	-22,045,000	-8,328,000	-29,341,000	-14,265,000	-6,005,000	13,443,000	9,191,000	7,036,000	4,145,000
Net Income Margin	3.7%	-1.81	-1.88	-1.69	-1.64	-1.54	-1.47	-1.41	-1.34	-1.23	-1.08	-0.81	-0.86	-	-	-	-	-	-	-	-	-
Free Cashflow	-17.4%	-30,269,000	-25,775,000	-22,970,000	-34,279,000	-16,166,000	-38,797,000	-16,971,000	-29,853,000	-26,449,000	-13,634,000	-21,054,000	-29,905,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-3.5%	414	428	462	495	326	348	375	385	407	441	439	450	468	481	486	512	514	511	490	473	462
Current Assets	-10.1%	351	390	423	448	271	284	312	313	342	327	319	321	428	446	437	413	403	441	402	451	424
Cash Equivalents	59.1%	64.00	40.00	85.00	95.00	73.00	42.00	44.00	28.00	41.00	99.00	57.00	5.00	77.00	55.00	87.00	100	74.00	28.00	51.00	94.00	106
Net PPE	27.7%	15.00	12.00	12.00	12.00	11.00	9.00	6.00	5.00	5.00	5.00	6.00	7.00	7.00	8.00	9.00	9.00	10.00	10.00	11.00	11.00	11.00
Liabilities	4.6%	247	237	246	257	57.00	47.00	54.00	47.00	48.00	56.00	39.00	33.00	32.00	29.00	31.00	31.00	28.00	29.00	27.00	25.00	25.00
Current Liabilities	-12.5%	55.00	62.00	63.00	68.00	32.00	23.00	30.00	23.00	31.00	38.00	36.00	29.00	27.00	23.00	24.00	24.00	20.00	19.00	23.00	21.00	20.00
Shareholder's Equity	-13.4%	166	192	217	238	269	301	321	338	359	384	399	418	436	452	456	481	486	482	462	448	436
Retained Earnings	-13.0%	-271	-240	-206	-178	-139	-102	-73.18	-46.83	-15.13	18.00	49.00	73.00	97.00	119	128	157	171	177	164	155	148
Additional Paid-In Capital	1.3%	438	433	425	418	411	405	398	388	377	367	351	345	339	332	327	322	314	305	298	293	289
Shares Outstanding	0.1%	21.00	21.00	21.00	21.00	21.00	21.00	21.00	21.00	20.00	20.00	20.00	20.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	800	-	-	-	1,262	-	-	-	865	-	-	-	754	-	-	-	1,408

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-14.5%	-28,601	-24,988	-21,602	-32,128	-13,783	-35,641	-15,534	-29,602	-26,375	-13,271	-21,021	-29,506	-4,579	-14,890	-15,461	-4,488	14,674	12,363	8,545	2,533	30,086
Share Based Compensation	-31.3%	5,561	8,099	6,716	6,998	7,363	7,139	6,833	7,603	6,471	6,062	5,353	5,475	5,280	4,883	4,745	4,754	4,978	5,098	4,512	4,164	4,707
Cashflow From Investing	546.9%	58,624	-13,117	11,836	-145,748	46,765	33,569	28,231	16,220	-35,055	45,501	72,683	-43,705	25,458	-17,445	2,504	26,779	27,748	-37,201	-52,208	-14,847	1,322
Cashflow From Financing	12.7%	-6,414	-7,350	-23.00	199,875	-2,027	301	2,930	4,120	3,351	9,632	943	686	1,152	299	233	3,226	4,358	1,166	687	490	257

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ENTA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Total revenue	$ 17,054	$ 17,795	$ 35,057	$ 41,380
Operating expenses:
Research and development	35,585	43,468	71,956	84,370
General and administrative	14,235	13,778	30,753	26,474
Total operating expenses	49,820	57,246	102,709	110,844
Loss from operations	(32,766)	(39,451)	(67,652)	(69,464)
Other income (expense):
Interest expense	(2,563)	0	(6,004)	0
Interest and investment income, net	3,809	1,837	8,107	2,830
Total other income, net	1,246	1,837	2,103	2,830
Loss before income taxes	(31,520)	(37,614)	(65,549)	(66,634)
Income tax benefit (expense)	363	(44)	985	(10)
Net loss	$ (31,157)	$ (37,658)	$ (64,564)	$ (66,644)
Net loss per share:
Basic	$ (1.47)	$ (1.79)	$ (3.06)	$ (3.19)
Diluted	$ (1.47)	$ (1.79)	$ (3.06)	$ (3.19)
Weighted average shares outstanding:
Basic	21,167	21,035	21,128	20,882
Diluted	21,167	21,035	21,128	20,882
Royalty [Member]
Total revenue	$ 17,054	$ 17,795	$ 35,057	$ 40,380
License [Member]
Total revenue	$ 0	$ 0	$ 0	$ 1,000

ENTA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 63,542	$ 85,388
Short-term marketable securities	236,768	284,522
Accounts receivable	7,756	8,614
Prepaid expenses and other current assets	10,932	13,263
Income tax receivable	32,031	31,004
Total current assets	351,029	422,791
Property and equipment, net	15,479	11,919
Operating lease, right-of-use assets	42,894	22,794
Restricted cash	3,968	3,968
Other long-term assets	187	803
Total assets	413,557	462,275
Current liabilities:
Accounts payable	6,726	4,097
Accrued expenses and other current liabilities	10,630	18,339
Liability related to the sale of future royalties	33,671	35,076
Operating lease liabilities	3,581	5,275
Total current liabilities	54,608	62,787
Liability related to the sale of future royalties, net of current portion	147,776	159,429
Operating lease liabilities, net of current portion	43,412	21,238
Series 1 nonconvertible preferred stock	1,423	1,423
Other long-term liabilities	224	663
Total liabilities	247,443	245,540
Commitments and contingencies (Note 11)
Stockholders' equity:
Common stock; $0.01 par value per share, 100,000 shares authorized; 21,179 and 21,059 shares issued and outstanding at March 31, 2024 and September 30, 2023, respectively	212	211
Additional paid-in capital	438,128	424,693
Accumulated other comprehensive loss	(667)	(1,174)
Accumulated deficit	(271,559)	(206,995)
Total stockholders' equity	166,114	216,735
Total liabilities and stockholders' equity	$ 413,557	$ 462,275

About Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Jay R. Luly Ph.D.
WEBSITE	enanta.com
INDUSTRY	Biotechnology
EMPLOYEES	160

Enanta Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Enanta Pharmaceuticals Inc? What does ENTA stand for in stocks?

ENTA is the stock ticker symbol of Enanta Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Enanta Pharmaceuticals Inc (ENTA)?

As of Mon May 13 2024, market cap of Enanta Pharmaceuticals Inc is 273.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ENTA stock?

You can check ENTA's fair value in chart for subscribers.

What is the fair value of ENTA stock?

You can check ENTA's fair value in chart for subscribers. The fair value of Enanta Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Enanta Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ENTA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Enanta Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ENTA is over valued or under valued. Whether Enanta Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Enanta Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENTA.

What is Enanta Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, ENTA's PE ratio (Price to Earnings) is -2.08 and Price to Sales (PS) ratio is 3.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENTA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Enanta Pharmaceuticals Inc's stock?

In the past 10 years, Enanta Pharmaceuticals Inc has provided -0.098 (multiply by 100 for percentage) rate of return.